In November 2024, ClearPoint Neuro, Inc. (the “Company”) entered into an At-The-Market Equity Offering Sales Agreement (the “Original Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated, as sales agent (the “Agent”), to sell shares of the Company’s common stock having aggregate sales proceeds of up to $50 million (the “Shares”), from time to time, through an “at the market offering” program, as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”). On November 18, 2026, the Company and the Agent entered into an amendment to the Original Sales Agreement (the “Sales Agreement Amendment,” and collectively with the Original Sales Agreement, the “Sales Agreement”) to increase the amount of aggregate sales proceeds from sales of shares of the Company’s common stock thereunder from $50,000,000 to $150,000,000, inclusive of the aggregate sales proceeds from sales of shares of the Company’s common stock under the Original Sales Agreement.
|
ClearPoint Neuro Inc. is a commercial-stage medical device company that develops and commercializes integrated systems for minimally invasive neurosurgical procedures in the brain. The company operates two primary business segments: medical devices for neurosurgical applications and partnerships in the biologics and drug delivery space. Its core product, the ClearPoint system, is an integrated hardware, software, and disposable platform designed to guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. The portfolio includes the SmartFrame Array Neuro Navigation System, the SmartFrame OR Stereotactic System, and the ClearPoint Prism Neuro Laser Therapy System, which is manufactured by CLS. In 2025, the company acquired IRRAS Holdings, Inc., adding the IRRAflow Active Fluid Exchange System to its lineup for neurocritical care and intracranial fluid management. The second segment provides preclinical development services, including protocol consultation and in vivo biology services, to support pharmaceutical and biotech partners in gene and cell therapy trials. The company serves healthcare and research centers in North America, Europe, Asia, and South America, with partners ranging from academic institutions to contract research organizations. ClearPoint Neuro was incorporated in 1998 and has expanded its capabilities from MRI-guided interventions to operating room settings and acute care environments. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage clearpointneuro.com |
| Sector Healthcare | IR page ir.clearpointneuro.com | |
|
Tags
neurosurgery, deep brain stimulation, laser ablation, intracranial pressure monitoring, gene therapy delivery, cell therapy delivery, neurocritical care, preclinical research, biologics, drug delivery, stereotactic surgery, mri guidance, ClearPoint system, SmartFrame Array Neuro Navigation System, SmartFrame OR Stereotactic System, ClearPoint Prism Neuro Laser Therapy System, IRRAflow Active Fluid Exchange System, IRRAS Holdings Inc., CLS, SmartFlow Neuro cannula, SmartFrame trajectory device, SmartGrid patch, ClearPoint Maestro Brain Model, Thermoguide software, ClearPoint Navigation Software
|
Press page ir.clearpointneuro.com/news-events/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 391.349M |
| Market cap (USD) | $ 391.349M |
| P/E | -10.18 |
| PEG | — |
| P/BV | 14.35 |
| P/S | 8.60 |
| P/OCF | -12.16 |
| P/FCF | -11.78 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -95.6% |
| ROI | -33.1% |
| ROIC | -23.5% |
| Profit margin | -69.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 186.5% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 21 |
| Quality score | -44.4% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.971M | 31.39M | 23.955M | 20.551M | 16.299M | 12.829M | 11.217M | 7.353M | 7.38M | 5.749M | 4.594M | 3.604M | 3.931M | 5.058M | 3.818M |
| Net profit | -25.54M | -18.914M | -22.089M | -16.435M | -14.41M | -6.782M | -5.54M | -6.163M | -7.167M | -8.07M | -8.449M | -4.525M | -7.086M | -5.707M | -8.311M |
| Free cash flow | -24.447M | -9.225M | -14.437M | -16.42M | -12.865M | -7.848M | -2.86M | -4.694M | -6.019M | -5.921M | -8.715M | -7.298M | -7.852M | -7.561M | -6.266M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 865,943 | 949,415 | 1.23M | 1.09M | 1.88M | 2.34M | 2.67M | 3.21M | 4.71M | 6.55M |
| ↳ YoY growth | -28.9% | +9.6% | +30.0% | -11.7% | +72.6% | +24.2% | +14.0% | +20.5% | +46.8% | +39.0% |
| ↳ 5y CAGR | +16.6% | +16.3% | +9.9% | +18.4% | +9.1% | +22.0% | +22.9% | +21.1% | +34.0% | +28.3% |
| Lease liabilities (USD) | — | — | — | 390,189 | 2.84M | 2.45M | 2.09M | 3.99M | 3.57M | 9.16M |
| Cash and deposits (USD) | 3.32M | 9.29M | 3.1M | 5.7M | 20.1M | 54.1M | 27.6M | 23.1M | 20.1M | 45.9M |
| Intangible assets (USD) | — | — | — | — | — | — | — | — | 0.00 | 13.9M |
| Right-of-use assets (USD) | — | — | — | 374,218 | 2.74M | 2.24M | 1.9M | 3.56M | 3.09M | 8.43M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -5.82M | -5.99M | -4.63M | -2.85M | -7.81M | -12.7M | -16.2M | -13.7M | -8.95M | -23.9M |
| Purchases of property, plant and equipment (USD) | -101,002 | -26,752 | -63,490 | -10,190 | -41,000 | -168,000 | -253,000 | -717,000 | -275,000 | -522,000 |
| Purchases of intangible assets (USD) | — | — | — | — | — | 0.00 | -893,000 | -334,000 | 0.00 | — |
| Change in receivables (cash effect) (USD) | 352,100 | -83,472 | -284,481 | 143,979 | -791,000 | -658,000 | -211,000 | -1.8M | -1.21M | -268,000 |
| Change in inventories (cash effect) (USD) | 72,342 | -469,922 | 122,220 | -1.02M | -25,000 | -1.71M | -4.42M | 1.25M | 743,000 | -103,000 |
| Change in payables (cash effect) (USD) | 178,419 | -512,362 | -284,322 | 1.17M | -459,000 | 1.29M | 1.59M | -649,000 | 3.11M | -7.52M |
| Interest paid (cash effect) (USD) | -976,295 | -348,528 | -210,722 | -316,558 | -1.58M | -597,000 | -523,000 | -743,000 | -480,000 | -908,000 |
| Income taxes paid (cash effect) (USD) | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | -62,000 | -69,000 |
| Share-based compensation (USD) | 959,585 | 1.25M | 1.23M | 799,111 | 1.09M | 2.08M | 4.13M | 6.08M | 6.91M | 8.18M |
| Operating cash flow before change in receivables (USD) | -6.17M | -5.91M | -4.35M | -2.99M | -7.02M | -12M | -16M | -11.9M | -7.74M | -23.7M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -5.92M | -6.02M | -4.69M | -2.86M | -7.85M | -12.9M | -17.3M | -14.8M | -9.23M | -24.4M |
| Income detail | ||||||||||
| Research and development expense (USD) | 2.63M | 2.81M | 2.31M | 2.92M | 4.69M | 8.99M | 10.9M | 11.7M | 12.4M | 13.9M |
| ↳ 5y CAGR | -9.2% | +2.5% | -4.6% | -2.4% | +19.1% | +27.9% | +31.1% | +38.3% | +33.5% | +24.3% |
| Provision for credit losses (USD) | — | — | — | — | 27,000 | 202,000 | -117,000 | 1.26M | -296,000 | 21,000 |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | 1.8% | 9.6% | 4.7% | 42.8% | 7.5% | 0.4% |
| Reported | Mar 9, 2017 | Mar 21, 2018 | Apr 1, 2019 | Mar 27, 2020 | Mar 9, 2022 | Mar 1, 2023 | Mar 1, 2023 | Mar 12, 2024 | Mar 17, 2026 | Mar 17, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
October 28, 2026 4:05pm EDT Download as PDF
Related Documents
Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million
SOLANA BEACH, CA / ACCESS Newswire / October 28, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.
Third Quarter 2026 Highlights
- Reported third quarter revenue of $12.1 million, representing 36% overall growth, including the recently acquired IRRA_flow_ Portfolio;
- Neurosurgery navigation and therapy, which includes navigation, laser, drill and IRRA_flow_ products, increased 59% to $5.4 million in the quarter;
- Achieved record capital equipment and software revenue of $1.7 million, representing 68% growth in the quarter, including the recently acquired IRRA_flow_ equipment;
- Increased biologics and drug delivery revenue to $4.9 million, an 11% year-over-year increase;
- First formal BLA was submitted by one partner for the treatment of Huntington's Disease;
- ClearPoint is an industry partner in a five-year, $2.98 million competitively awarded NCI R01, led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases.¹ The program runs from benchtop through large subject validation to a clinical trial, using the ClearPoint Prism system. ClearPoint contributes technical, software development, and procedural expertise. This is early-stage research that supports our spine LITT roadmap;
- Received net proceeds of $22.0 million from the at-the-market equity offering program; and
- Reported cash and cash equivalents of $46.2 million as of September 30, 2026.
"Throughout 2026 we have continued to make substantial strategic progress in building our comprehensive drug delivery ecosystem, adding new biopharma partners, and assisting existing partners progress through the regulatory process globally," commented Joe Burnett, President and CEO at ClearPoint Neuro. "The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth. The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRA_flow_ product integration has enabled improved operating leverage. Our current cash balance of $46.2 million provides us with additional confidence to fund our product pipeline which now includes AI Derived Planning and Simulation, Neuro Navigation in the MRI and Operating Room, Laser Therapy and Access, IRRA_flow_ CSF management, Robotic Surgery, Focused Ultrasound, as well as our comprehensive drug delivery ecosystem including pre-clinical and clinical services. This unmatched portfolio and partnership advantage will make us the premier therapy enabling company in the cranial neurosurgery space for many years to come."
Business Outlook
The Company now estimates revenue in 2026 to be between $48.0 million and $50.0 million.
Financial Results - Quarter Ended September 30, 2026
Total revenue was $12.1 million for the three months ended September 30, 2026, and $8.9 million for the three months ended September 30, 2025, which represents an increase of $3.2 million, or 36%.
Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased 11% to $4.9 million for the three months ended September 30, 2026 from $4.4 million for the three months ended September 30, 2025. This increase is primarily attributable to higher revenue from services performed at ClearPoint Advanced Laboratories.
Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRA_flow_ systems, increased 59% to $5.4 million for the three months ended September 30, 2026, from $3.4 million for the same period in 2025. The increase is driven primarily by additional revenues due to sales of the IRRA_flow_ product, which the Company acquired in connection with its acquisition of IRRAS in the fourth quarter of 2025.
Capital equipment and software revenue, consisting of sales of ClearPoint and IRRA_flow_ reusable hardware and software and related services, increased 68% to $1.7 million for the three months ended September 30, 2026, from $1.0 million for the same period in 2025 primarily due to an increase in placements of ClearPoint navigation capital and software, IRRA_flow_ control units, and Prism laser units.
The Company achieved a gross margin of 58% on its sales for the three months ended September 30, 2026, and a gross margin of 63% in the same period in 2025. The decrease in gross margin is primarily due to overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortization expense of acquired intangible assets, partially offset by a decrease in other cost of revenue, for the three months ended September 30, 2026, as compared to the same period in 2025.
Operating expenses were $13.4 million for the three months ended September 30, 2026, compared with $10.9 million for the same period in 2025, an increase of 23%. The increase was mainly driven by the IRRAS acquisition in November 2025, primarily through higher personnel costs resulting from the expansion of our clinical and sales teams, as well as increased occupancy costs, and travel costs.
At September 30, 2026, the Company had cash and cash equivalents totaling $46.2 million as compared to $45.9 million at December 31, 2025, with the increase resulting from the net proceeds of $22.0 million from the at-the-market equity offering program, partially offset by the use of $20.1 million in cash for operating activities.
¹ Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under award number R01CA307001. A total of $633,819, or 100 percent of the first-year project budget, is financed with federal funds. No non-governmental funds are included in the approved budget. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Teleconference Information
Investors and analysts are invited to listen to a live broadcast review of the Company's third quarter 2026 results on Wednesday, October 28, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=cPBDKSsR . Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until November 27, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/ .
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com .
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the meaning of the federal securities laws, including the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: the Company's 2026 revenue guidance and other expectations regarding future financial performance, liquidity and capital resources; the expected adoption and growth of the Company's neurosurgery navigation and therapy products, including IRRA_flow_ and laser therapy, and its capital equipment and software placements; the growth of the Company's biologics and drug delivery business, including preclinical services at ClearPoint Advanced Laboratories; the regulatory progress of the Company's biologics and drug delivery partners; the expansion of the Company's laser therapy program into spine; the development of the Company's product pipeline; and other statements of management's expectations, beliefs, plans, estimates or projections relating to the future. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "potential," "may," "will," "should," "could" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements.
Factors that could cause actual results to differ materially include, among others: the Company's ability to achieve broader market adoption of its products and services; the timing and outcome of its biologics and drug delivery partners' clinical trials and regulatory submissions; the Company's ability to maintain and expand its partner relationships; the risk that ClearPoint Advanced Laboratories may not achieve or maintain GLP compliance or generate revenue on anticipated timelines; the integration of acquired businesses, including IRRAS; changes in government regulation, reimbursement and funding; competition; supply chain disruptions; the Company's ability to fund its operations and service its indebtedness; and general economic, market and geopolitical conditions. For a more detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q, including the "Risk Factors" sections therein. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Oct 28, 2026 4:30 pm EST
A replay is available until November 27, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671.
©2026 ClearPoint Neuro, Inc. All Rights Reserved.
Privacy Policy Cookie Policy Terms of Use California Compliance Declaration Sitemap
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Feb 12, 2020 | Renamed | MRI INTERVENTIONS, INC. → CLEARPOINT NEURO, INC. |
| Jul 15, 2011 | Renamed | SURGIVISION INC → MRI INTERVENTIONS, INC. |
ETFs Holding ClearPoint Neuro Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| VFMO | 0.02% | 22,060 | $ 333.988K | Aug 31, 2026 |